MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Common Equity of $254.0 million for Q1 2026, down 38.43% year-over-year from $412.6 million in Q1 2025, and down 16.57% quarter-over-quarter from $304.5 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Common Equity (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $254.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 38.43% year-over-year to $254.0 million; the TTM figure through Mar 2026 stood at $254.0 million (down 38.43% YoY), while the FY2025 annual figure was $304.5 million, down 32.84% from the prior year.
- Common Equity for Q1 2026 stood at $254.0 million, down from $304.5 million in the prior quarter.
- The five-year high for Common Equity was $552.4 million in Q1 2024, with the low at -$25.3 million in Q1 2022.
- The 5-year median for Common Equity is $357.9 million (2025), against an average of $319.6 million.
- Peak annual rise in Common Equity reached 11310.99% in 2022, while the deepest fall reached 10205.8% in 2022.
- MoonLake Immunotherapeutics' Common Equity stood at $68.8 million in 2022, then soared by 646.71% to $513.5 million in 2023, then decreased by 11.7% to $453.4 million in 2024, then sank by 32.84% to $304.5 million in 2025, then slipped by 16.57% to $254.0 million in 2026.
- Business Quant data shows MLTX's Common Equity at $254.0 million in Q1 2026, $304.5 million in Q4 2025, and $291.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 428.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 428.20 Mn |
| Mar 31, 2026 | 254.02 Mn |
| Dec 31, 2025 | 304.48 Mn |
| Sep 30, 2025 | 291.19 Mn |
| Jun 30, 2025 | 357.94 Mn |
| Mar 31, 2025 | 412.58 Mn |
| Dec 31, 2024 | 453.39 Mn |
| Sep 30, 2024 | 495.50 Mn |
| Jun 30, 2024 | 530.03 Mn |
| Mar 31, 2024 | 552.39 Mn |
| Dec 31, 2023 | 513.49 Mn |
| Sep 30, 2023 | 489.64 Mn |
| Jun 30, 2023 | 499.11 Mn |
| Mar 31, 2023 | 59.11 Mn |
| Dec 31, 2022 | 68.77 Mn |
| Sep 30, 2022 | 82.57 Mn |
| Jun 30, 2022 | 94.56 Mn |
| Mar 31, 2022 | -25.27 Mn |
| Dec 31, 2021 | -11.65 Mn |
| Sep 30, 2021 | -3.10 Mn |